AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02693314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)
Description: One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
Study NCT02693314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
Study NCT03261531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
Study NCT01028625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
Study NCT01028625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure Self-care Education
Description: Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
Study NCT01028625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heart Failure Self-care Education
Description: Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
Study NCT00875355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study NCT00875355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo radiotherapy
Study NCT04432363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
Study NCT04432363 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
Study NCT04479800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: Form: capsule; Route of administration: oral
Study NCT04459455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contain COVID Anxiety SSI
Description: Participants first receive normalizing scientific information (including neuroscience findings) that help explain why increased anxiety during the COVID-19 is a typical response. They then read testimonials from three other people around the world who have applied a 3-step action plan for coping more effectively with their anxiety. The entire intervention takes approximately 8 minutes and is completely entirely within the Qualtrics survey platform.
Study NCT04459455 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Remain COVID Free SSI
Description: This placebo SSI was developed to mirror the structure of the Contain COVID Anxiety SSI, discuss COVID-19 related content, and do so without as many of the potential active ingredients of effective SSIs. Participants will receive scientific information about how soap kills the COVID-19 virus, but no neuroscience information related to behaviors or behavior change.
Study NCT04082260 — intervention group
Intervention type: DRUG
Intervention: Alemtuzumab Injection [Lemtrada]
Description: Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days.
Study NCT02337088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping at 30 seconds
Description: For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
Study NCT02337088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping at 60 seconds
Description: For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
Study NCT01395992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
Study NCT01395992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 10 mg tablet, SL BID for 182 days
Study NCT02666014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal of neuromuscular blockade
Study NCT02666014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of neuromuscular blockade
Study NCT04347083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic test
Description: Muscle spindle- based reflex latency will be measured
Study NCT02543138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trocar
Description: Closed thoracostomy using the new trocar
Study NCT02443064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on.
Study NCT03892447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d
Study NCT03892447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Ferulate
Description: Sodium Ferulate 2\~6mg/kg.d,iv,14d
Study NCT03892447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d
Study NCT03892447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d
Study NCT03254966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
Study NCT03254966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT03087006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation (ASTM)
Description: Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone acetate
Description: Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 5 mg tablet of prednisone twice daily orally.
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Participants will receive 5 mg tablet of prednisone twice daily orally.
Study NCT03087006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care includes usual care of the participants including dry eye disease medications
Study NCT03287258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 program
Description: The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
Study NCT03287258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one program
Description: The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
Study NCT01298492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659
Description: 75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
Study NCT03880201 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound guided supraclavicular block
Description: The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves.
Study NCT03880201 — intervention group
Intervention type: DEVICE
Intervention: Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)
Description: Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
Study NCT02340663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOVA Bite Splint
Description: Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
Study NCT02340663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Michigan Bite Splint
Description: Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
Study NCT01078805 — intervention group
Intervention type: DRUG
Intervention: FORTEO
Description: prescribed in accordance with usual clinical practice for up to 24 months
Study NCT00511680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Based In-Home Intervention
Description: The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
Study NCT02997592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpinCare
Description: The burn wound is treated using the SpinCare Systen
Study NCT00704262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus hydrocortisone (LEO 80190)
Description: Once daily application
Study NCT01184937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs.
Study NCT04465682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Dip Home-Based Dipstick Analyzer
Description: Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
Study NCT01074138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391
Description: KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
Study NCT01331304 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: 600-900mg per day over 6 months
Study NCT01331304 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: 100-800mg a day over 6 months
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (Low-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (Low-dose without adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose without adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 0.9% normal saline
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 180
Study NCT01230957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 30, and 180
Study NCT03726684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coding strategy for cochlear implants
Description: Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: single intrathecal injection of ketorolac 2 mg
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subject will receive a placebo (preservative free normal saline) spinal injection
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: All subjects will receive a remifentanil infusion
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: All subjects will receive a remifentanil infusion
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical capsaicin pain model utilized for each subject
Study NCT00693160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: Topical capsaicin pain model utilized for each subject
Study NCT04435223 — intervention group
Intervention type: BIOLOGICAL
Intervention: biological assays in particular on the lipid metabolism
Description: bioassays carried out on samples already collected and conserved
Study NCT05728294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block with ropivacaine 0.5%, 20 ml
Description: Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
Study NCT05728294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block with ropivacaine 0.5%, 20 ml
Description: Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
Study NCT02803073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone Cypionate Intramuscular injections will be administered weekly
Study NCT02803073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline Intramuscular injections will be administered weekly
Study NCT01676285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Study NCT01676285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04177719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: oxytocin will be given intranasally. The order of administration will be counterbalanced
Study NCT04177719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be given intranasally. The order of administration will be counterbalanced
Study NCT02544412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: novel mindfulness-based well-being training
Study NCT04147351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection; bevacizumab Injection
Description: a PD-L1 inhibitor; anti-angiogenesis
Study NCT00317148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo capsule
Study NCT00317148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA capsule
Description: One capsule of DHEA
Study NCT03198130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: Intravenous (IV) use
Study NCT00727363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
Study NCT00727363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
Study NCT01014585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally twice daily
Study NCT01014585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Milnacipran tablets administered orally twice daily
Study NCT04218097 — intervention group
Intervention type: OTHER
Intervention: Study questionnaire
Description: Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
Study NCT02257736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to apalutamide once daily orally.
Study NCT02154425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast milk sampling
Description: Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
Study NCT02154425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.